These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The impact of immunopeptidomics: From basic research to clinical implementation. Shapiro IE; Bassani-Sternberg M Semin Immunol; 2023 Mar; 66():101727. PubMed ID: 36764021 [TBL] [Abstract][Full Text] [Related]
9. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome. Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780 [TBL] [Abstract][Full Text] [Related]
10. Spliced HLA-bound peptides: a Black Swan event in immunology. Faridi P; Dorvash M; Purcell AW Clin Exp Immunol; 2021 May; 204(2):179-188. PubMed ID: 33644851 [TBL] [Abstract][Full Text] [Related]
11. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility. Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C Front Immunol; 2018; 9():872. PubMed ID: 29774024 [TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins. ElAbd H; Franke A Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028 [TBL] [Abstract][Full Text] [Related]
13. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723 [TBL] [Abstract][Full Text] [Related]
14. Know thy immune self and non-self: Proteomics informs on the expanse of self and non-self, and how and where they arise. Joyce S; Ternette N Proteomics; 2021 Dec; 21(23-24):e2000143. PubMed ID: 34310018 [TBL] [Abstract][Full Text] [Related]
15. Identification of the Cryptic HLA-I Immunopeptidome. Erhard F; Dölken L; Schilling B; Schlosser A Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536 [TBL] [Abstract][Full Text] [Related]
16. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma. Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703 [TBL] [Abstract][Full Text] [Related]
17. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications. Sidney J; Vela JL; Friedrich D; Kolla R; von Herrath M; Wesley JD; Sette A BMC Immunol; 2018 Mar; 19(1):12. PubMed ID: 29562882 [TBL] [Abstract][Full Text] [Related]
18. Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Krensky AM; Clayberger C Int Rev Immunol; 1996; 13(3):173-85. PubMed ID: 8782740 [TBL] [Abstract][Full Text] [Related]
19. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358 [TBL] [Abstract][Full Text] [Related]
20. HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance. Ramarathinam SH; Ho BK; Dudek NL; Purcell AW Proteomics; 2021 Sep; 21(17-18):e2000160. PubMed ID: 34357683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]